Status:
UNKNOWN
Effects of Aortic Valve Replacement on Myocardial T1 Values in Severe Aortic Valve Stenosis
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
Danish Cardiovascular Academy (DCA)
Eva og Henry Frænkels Mindefond
Conditions:
Aortic Valve Stenosis
Aortic Valve Replacement
Eligibility:
All Genders
18+ years
Brief Summary
Background: Severe aortic valve stenosis (AS) is the commonest valve disease. Aortic valve replacement (AVR) is primarily indicated when symptoms occur and/or when there is a drop in left ventricular ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Severe aortic valve stenosis (Vmax \> 4 m/s and/or mean gradient \>40 mmHg)
Exclusion
- Reduced left ventricular ejection fraction (\<50%)
- More than mild left-sided valvular insufficiency
- Previous or planned primary coronary intervention (PCI) or coronary artery by-pass grafting (CABG)
- Persistent atrial fibrillation
- Contraindications for CMR (pregnancy, severe claustrophobia, magnetic metallic implants)
- Pacemaker/ICD
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05404100
Start Date
April 1 2021
End Date
April 1 2024
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen O, Denmark, 2100